Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Trial Bill to be Tabled (India)

This article was originally published in PharmAsia News

Executive Summary

The proposed Central Drug Authority (CDA) bill that includes imprisonment of five years and a fine of Rs 20 lakh for those found violating norms of clinical trials will be tabled during the upcoming monsoon session of the Parliament. Drugs controller general of India Dr M. Venkateswarulu says the CDA bill has been framed with an aim to check the increasing clinical trials being conducted in the country. "As of today, there's no act or law to monitor the clinical research and drug trials in the country," he states. "There cannot be any compromise in clinical research and the trials that are being done in the country," he adds. "There is need for more transparency and knowing about the associated risk factors." He further says the draft CDA bill is ready, and the Parliament will take a decision on the final quantum of punishment. Expressing concern over the growing tendency of pharma industry to outsource work, he asserts there should be a limit to outsourcing of work. "The people who undergo clinical trials of drugs should not be exploited. They should be well informed about the risks. Their safety should be ensured. There should be proper communication with people while conducting trials." Thomas Adam, president and chief executive officer of the Association of Clinical Research Professionals (ACRP), says clinical trials will begin to 'migrate' to India in large numbers. "Young talent will be the driving force in attracting this to India," he says. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts